Similar lineage transitions are observed in other cancers treated with targeted therapies, for example, EGFR-, ALK- and KRASG12C-mutant lung adenocarcinoma, underscoring the broad relevance of lineage plasticity in tumor progression and therapy resistance7–11. This evidence concerns the gene ALK and lung adenocarcinoma.